STOCK TITAN

Agilent Technologies Inc. - A STOCK NEWS

Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.

Agilent Technologies Inc., originally spun out of Hewlett-Packard in 1999, has evolved into a leading firm in the life sciences and diagnostics sector. The company specializes in creating advanced measurement technologies that serve a vast range of customers across various industries.

The company's core business revolves around three main segments: life science and applied tools, cross lab (which includes consumables and services related to life sciences and applied tools), and diagnostics and genomics. These segments collectively cater to a broad spectrum of markets, including biopharmaceuticals, chemicals, advanced materials, clinical labs, environmental testing, forensics, food safety, academic research, and government-related organizations.

Agilent's geographical reach is extensive, with significant operations in the U.S. and China. The company is committed to addressing global trends impacting human health and the environment and continuously anticipates future scientific needs.

Agilent provides comprehensive laboratory solutions that enhance the efficiency of laboratories, from sample preparation to data interpretation and management. Their instruments, software, services, and consumables are designed to meet the most complex laboratory demands, empowering scientists and researchers worldwide to make impactful discoveries and improvements in various fields.

Recent achievements include advancements in biopharmaceutical technology, collaborations with leading research institutions, and the launch of state-of-the-art diagnostic tools. The company also emphasizes sustainable practices and innovations aimed at improving human health and environmental outcomes.

Rhea-AI Summary

Agilent Technologies Inc. (NYSE: A) released its 19th annual Corporate Social Responsibility (CSR) report, detailing its 2019 achievements and actions in response to the 2020 global pandemic. Key highlights include 17% reduction in CO2 emissions per square foot, 85% solid waste diversion from landfills, and $7.5 million in philanthropic investments. Recognized as Barron’s no. 1 Most Sustainable Company for 2019, Agilent emphasizes environmental, social, and governance (ESG) strategies aimed at enhancing the quality of life globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
-
Rhea-AI Summary

Agilent Technologies Inc. (NYSE: A) announces the adoption of its clinical informatics platform, Alissa Interpret, by the North West Genomic Laboratory Hub (NW GLH) in England. This platform enhances genomic testing capabilities by standardizing variant analysis and reporting on next-generation sequencing (NGS) data. Designed for efficiency, it integrates various genomic data types, supporting the interpretation of both rare diseases and cancer genomics. Agilent aims to improve diagnostic accuracy and reduce analysis time, addressing the growing demand for genomic testing solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
none
Rhea-AI Summary

Agilent Technologies Inc. (NYSE: A) has unveiled its new Agilent 7850 ICP-MS System, designed to enhance productivity in ICP-MS analysis workflows. This innovative instrument features smart tools aimed at minimizing common time traps that can waste time and increase costs, particularly benefiting less experienced users in small to medium contract labs. The 7850's advanced software streamlines instrument setup and workflow, helping labs achieve high-quality results efficiently. With a revenue of $5.34 billion in fiscal 2020, Agilent continues to lead in the life sciences and diagnostics sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
-
Rhea-AI Summary

Agilent Technologies Inc. (NYSE: A) has launched the Biomarker Pathologist Training Program, aimed at enhancing the ability of pathologists to accurately score biomarkers. This global initiative, initially available in Europe and North America, leverages Agilent's expertise in companion diagnostics and partnerships with pharmaceutical firms. The program includes both basic and advanced training, offered digitally via Pathcore Scholar. It is designed to improve patient outcomes by ensuring high concordance in biomarker scoring, critical for the increasing prevalence of targeted therapies in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
none
-
Rhea-AI Summary

Agilent Technologies reported Q4 revenue of $1.48 billion, an 8% increase year-over-year, with GAAP net income of $222 million (71 cents per share). Non-GAAP net income reached $305 million (98 cents per share), surpassing last year's figures. The Life Sciences and Applied Markets Group posted $671 million in revenue, while the Diagnostics and Genomics Group generated $294 million. For fiscal year 2021, revenue is projected between $5.6 billion and $5.7 billion, with non-GAAP EPS guidance of $3.57 to $3.67.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
Rhea-AI Summary

Agilent Technologies Inc. (NYSE: A) launched the NanoDis System for nanoparticle dissolution testing, designed to ensure compliance with 21 CFR Part 11 regulations. Developed in collaboration with MyBiotech GmbH, this system enhances the efficiency of R&D and manufacturing workflows by providing an automated process for consistent QC of new drug formulations. The NanoDis System is recognized as a finalist for the CPhI Pharma Awards, highlighting its innovative role in advancing pharmaceutical quality control.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
-
Rhea-AI Summary

Agilent Technologies, Inc. (NYSE: A) has announced an increase in its quarterly dividend to 19.4 cents per share, reflecting an 8% rise over the previous quarter. The dividend payment is set for January 27, 2021, to shareholders on record as of January 5, 2021. Future dividend amounts are subject to board approval. Agilent continues to operate as a leader in life sciences, diagnostics, and applied chemical markets, generating $5.16 billion in revenue in fiscal 2019 and employing over 16,300 individuals globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
dividends
-
Rhea-AI Summary

Agilent Technologies (NYSE: A) has awarded the Agilent Thought Leader Award to professors Carl H. June and Michael Milone for their contributions to CAR T-cell cancer immunotherapy, notably the co-development of tisagenlecleucel (Kymriah™). The partnership aims to establish standards in cell-based cancer therapeutics through advanced CRISPR technology and Agilent's instruments such as the xCELLigence RTCA eSight and 6546 LC/Q-TOF Mass Spectrometer. This collaboration is expected to enhance cancer treatment methodologies and improve the quality of T-cell engineering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
Rhea-AI Summary

Agilent Technologies (NYSE: A) has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx to help identify patients with triple-negative breast cancer (TNBC) for treatment with KEYTRUDA® (pembrolizumab). This assay is the only FDA-approved companion diagnostic for this purpose, enhancing the ability of pathologists to determine PD-L1 expression, a key biomarker for the therapy. With this approval, Agilent strengthens its role in drug/diagnostic co-development, marking the seventh cancer type for which the test has been approved.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags

FAQ

What is the current stock price of Agilent Technologies (A)?

The current stock price of Agilent Technologies (A) is $132.06 as of November 21, 2024.

What is the market cap of Agilent Technologies (A)?

The market cap of Agilent Technologies (A) is approximately 37.6B.

What does Agilent Technologies Inc. specialize in?

Agilent specializes in life sciences, diagnostics, and measurement technologies, providing advanced solutions and services for laboratories.

When was Agilent Technologies Inc. founded?

Agilent Technologies was spun out of Hewlett-Packard in 1999.

What are the main business segments of Agilent Technologies Inc.?

Agilent operates in three main segments: life science and applied tools, cross lab, and diagnostics and genomics.

Which industries does Agilent Technologies Inc. serve?

Agilent serves industries such as biopharmaceuticals, chemicals, advanced materials, clinical labs, environmental testing, forensics, food safety, academic research, and government organizations.

Where are Agilent Technologies Inc.'s main operations located?

Agilent's main operations are located in the U.S. and China.

What recent achievements has Agilent Technologies Inc. made?

Recent achievements include advancements in biopharmaceutical technology, collaborations with research institutions, and new diagnostic tools.

How does Agilent Technologies Inc. contribute to laboratory efficiency?

Agilent enhances laboratory efficiency through comprehensive solutions for sample preparation, data interpretation, and management.

What sustainable practices does Agilent Technologies Inc. emphasize?

Agilent focuses on innovations that improve human health and environmental outcomes, emphasizing sustainability in its practices.

Why do scientists and researchers trust Agilent Technologies Inc.?

Scientists and researchers trust Agilent for its reliable solutions that meet complex laboratory demands and enable significant insights.

What kind of global issues does Agilent Technologies Inc. address?

Agilent addresses global issues related to human health and the environment, anticipating future scientific needs.

Agilent Technologies Inc.

NYSE:A

A Rankings

A Stock Data

37.62B
286.44M
0.27%
91.2%
1.2%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States of America
SANTA CLARA